CGRP

Overview

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide produced by alternative RNA splicing of the calcitonin gene (CALCA). It is one of the most potent endogenous vasodilators known and is widely distributed throughout the central and peripheral nervous systems, with particularly dense expression in trigeminal sensory neurons — a distribution that proved central to its emergence as the defining molecular target in migraine therapeutics.

CGRP exists in two isoforms:

• Alpha-CGRP — encoded by the CALCA gene on chromosome 11p15.2; the predominant form in sensory neurons and the primary isoform implicated in migraine pathophysiology
• Beta-CGRP — encoded by the CALCB gene; primarily expressed in the enteric nervous system; shares approximately 94% sequence homology with alpha-CGRP

The peptide was discovered in 1982 by Susan Amara and colleagues through analysis of alternative splicing of the Calcitonin gene. Despite being produced from the same gene, CGRP and calcitonin have distinct receptors, distributions, and biological functions. CGRP acts through its own receptor complex (CLR/RAMP1), while calcitonin signals through the calcitonin receptor.

The development of anti-CGRP therapies — including monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and small-molecule CGRP receptor antagonists known as "gepants" (ubrogepant, rimegepant, atogepant) — represents one of the most significant advances in headache medicine in decades. These were the first mechanism-specific preventive therapies developed for migraine.

Structure and Sequence

Alpha-CGRP is a 37-amino-acid peptide with a disulfide bridge and C-terminal amidation:

Sequence: Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH2

• Molecular weight: approximately 3,789.2 g/mol
• Key structural features:
  • Disulfide bridge: Between Cys2 and Cys7, forming a ring structure essential for receptor binding
  • C-terminal amidation: Required for biological activity; the C-terminal phenylalanine is amidated
  • N-terminal ring: The 1-7 disulfide loop is critical for receptor activation; truncation of the first residue produces a competitive antagonist (CGRP8-37)
  • Flexible central region: Residues 8-18 form a flexible hinge connecting the N-terminal ring to the C-terminal alpha-helix
  • C-terminal helix: Residues 19-37 form an amphipathic alpha-helix important for receptor affinity

The receptor for CGRP is a heteromeric complex consisting of calcitonin receptor-like receptor (CLR, a class B GPCR) and receptor activity-modifying protein 1 (RAMP1). RAMP1 is required for high-affinity CGRP binding and determines receptor pharmacology — CLR paired with RAMP2 or RAMP3 instead forms receptors for adrenomedullin.

Mechanism of Action

CGRP Receptor Signaling

The CGRP receptor (CLR/RAMP1) signals primarily through Gs-coupled activation of adenylate cyclase:

Primary signaling:

• Gs protein activation increases intracellular cAMP
• Protein kinase A (PKA) activation leads to smooth muscle relaxation (vasodilation) and neuronal sensitization
• In vascular smooth muscle, cAMP-mediated potassium channel opening produces hyperpolarization and relaxation

Additional pathways:

• Phospholipase C activation and intracellular calcium mobilization in some cell types
• MAPK/ERK signaling contributing to longer-term gene expression changes
• Receptor component protein (RCP) facilitates coupling efficiency

Trigeminal-Vascular System

CGRP is released from trigeminal sensory nerve terminals innervating cranial blood vessels (particularly meningeal arteries and the dura mater). During migraine:

1. Trigeminovascular activation releases CGRP from perivascular nerve endings
2. CGRP produces meningeal vasodilation and promotes neurogenic inflammation
3. Mast cell degranulation and plasma protein extravasation amplify the inflammatory response
4. Sensitization of trigeminal nociceptors leads to the throbbing, pulsatile headache characteristic of migraine
5. Elevated CGRP levels have been measured in jugular venous blood during migraine attacks, confirming its role in pain signaling

Cardiovascular Function

Beyond migraine, CGRP serves physiological roles as a cardiovascular protector:

• Potent vasodilator in coronary, cerebral, and mesenteric vascular beds
• Cardioprotective during ischemia-reperfusion injury
• Positive inotropic and chronotropic effects on cardiac tissue
• Participates in wound healing through promotion of angiogenesis

Research Summary

Pharmacokinetics

• Plasma half-life: approximately 6-10 minutes; rapidly degraded by neprilysin and other endopeptidases
• Normal plasma levels: 5-30 pg/mL; a biomarker elevated during migraine attacks
• CSF levels: present at low picomolar concentrations; elevated ictally in migraine
• Release mechanism: calcium-dependent exocytosis from large dense-core vesicles in sensory nerve terminals
• Distribution: trigeminal ganglia, dorsal root ganglia, perivascular nerve fibers, central nervous system, enteric nervous system
• Anti-CGRP mAb pharmacokinetics (erenumab): half-life approximately 28 days; monthly subcutaneous injection; does not cross blood-brain barrier, indicating peripheral mechanism of action
• Gepant pharmacokinetics (rimegepant): oral bioavailability approximately 64%; half-life approximately 11 hours; crosses BBB minimally

Common Discussion Topics

The Anti-CGRP Revolution in Migraine

The introduction of anti-CGRP therapies beginning in 2018 fundamentally changed migraine treatment. Prior preventive therapies (beta-blockers, anticonvulsants, antidepressants) were all repurposed drugs with significant side effect burdens and poor adherence rates. Anti-CGRP monoclonal antibodies offered the first mechanism-specific preventive treatments with favorable tolerability profiles. The subsequent approval of oral gepants provided additional options without the requirement for injection. This therapeutic class validated decades of basic research into CGRP's role in migraine pathophysiology.

Cardiovascular Safety Considerations

Because CGRP is a potent vasodilator with cardioprotective properties, long-term blockade has raised theoretical cardiovascular safety concerns. Animal studies suggest CGRP protects against hypertension and cardiac ischemia. However, clinical trial data and post-marketing surveillance through several years have not demonstrated significant cardiovascular adverse signals with anti-CGRP therapies. Whether this reflects the incomplete blockade achieved by therapeutic dosing, compensatory mechanisms, or true absence of risk with long-term use remains under investigation.

Peripheral vs. Central Mechanisms

A notable finding is that anti-CGRP monoclonal antibodies, which are too large to cross the blood-brain barrier in meaningful quantities, are effective migraine preventives. This implies that CGRP's migraine-relevant actions occur substantially in the peripheral trigeminovascular system (meninges, trigeminal ganglia) rather than centrally. Small-molecule gepants may additionally access central sites. The relative contributions of peripheral versus central CGRP signaling to migraine pathophysiology remain actively debated.

CGRP Beyond Migraine

Emerging research has examined CGRP's role in other pain conditions, wound healing, and cardiovascular disease. The peptide's involvement in inflammatory pain sensitization, arthritis, and neuropathic pain suggests potential therapeutic applications beyond headache. Conversely, exogenous CGRP administration has been explored as a cardioprotective agent in heart failure and ischemic syndromes, representing a pharmacological approach opposite to the anti-CGRP strategy used in migraine.

Dosing Protocols

As an endogenous neuropeptide, CGRP is not typically administered exogenously in research protocols. It is primarily studied as a biomarker and therapeutic target in migraine. The clinical relevance of CGRP biology is realized through anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) and small-molecule CGRP receptor antagonists (gepants: ubrogepant, rimegepant, atogepant) used for migraine prevention and treatment. CGRP itself is used in research settings for provocation testing in migraine studies.

Related Compounds

• Calcitonin — Derived from the same CALCA gene via alternative splicing; regulates calcium homeostasis through a distinct receptor
• Bradykinin — Another vasoactive peptide involved in pain and inflammation with complementary nociceptive roles
• VIP — A vasodilatory neuropeptide with overlapping cranial vascular effects, also elevated during some headache subtypes
• Endothelin-1 — A potent vasoconstrictor whose actions functionally oppose CGRP-mediated vasodilation